Skip to Content
Merck
All Photos(1)

Documents

35485

Supelco

2,4′-DDD

PESTANAL®, analytical standard

Synonym(s):

1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (2,4′-Dichlorodiphenyl)dichloroethane, o,p′-DDD, Mitotane

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
(ClC6H4)2CHCHCl2
CAS Number:
53-19-0
Molecular Weight:
320.04
Beilstein:
2056007
EC Number:
200-166-6
UNSPSC Code:
41116107
PubChem Substance ID:
329755170
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

agriculture
environmental

format

neat

SMILES string

ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl

InChI

1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

InChI key

JWBOIMRXGHLCPP-UHFFFAOYSA-N

Gene Information

human ... CYP11A1(1583) , CYP11B1(1584)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H351

Hazard Classifications

Carc. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCF3012
BCBS6884
BCBS6884V
SZB8233XV
SZE8233X

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

4,4′-DDT-d8 PESTANAL®, analytical standard

Supelco

34021

4,4′-DDT-d8

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Camille Baudry et al.
European journal of endocrinology, 167(4), 473-481 (2012-07-21)
Alternatives to transsphenoidal pituitary surgery may be required in Cushing's disease (CD) as a first- or second-line treatment. Mitotane is a potent anti-cortisolic drug but has been rarely investigated in the treatment of CD. Evaluation of the efficacy and tolerance
Martin Fassnacht et al.
The New England journal of medicine, 366(23), 2189-2197 (2012-05-04)
Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service